Divergent Mutational Landscapes and Clinical Outcomes in P53-Negative High-Grade Serous Ovarian Carcinoma Versus Cervical Cancer

Objective P53 negativity is a shared diagnostic feature of both some high-grade serous ovarian carcinoma (HGSOC) and cervical cancer, yet the underlying mechanisms remain poorly defined. This study aimed to elucidate the distinct pathogenic mechanisms and signaling dependencies that distinguish P53-negative HGSOC from P53-negative cervical cancer. Methods Hematoxylin and eosin (H&E) and P53 immunohistochemistry (IHC) were performed on archival HGSOC and cervical cancer cohorts. Clinical parameters were collected for P53-negative cases, followed by comprehensive molecular profiling using targeted next-generation sequencing (NGS). Differentially mutated genes were subjected to Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses. Results Patients with P53-negative HGSOC were significantly older (≥ 50 years: 81.25% vs. 50%, P < 0.05) and exhibited a five-fold higher mortality rate (25% vs. 5%) than the P53-negative cervical cancer cohort. Molecular profiling revealed that all 16 P53-negative HGSOC cases harbored deleterious TP53 mutations, whereas P53-negative cervical cancers showed wild-type TP53 but high mutation frequencies in PIK3CA (33.33%) and TERT (27.78%); notably, the P53-negative phenotype in cervical cancer was attributable to E6 oncoprotein-driven ubiquitin-mediated proteasomal degradation of wild-type P53 rather than to TP53 gene inactivation. Pathway analysis further distinguished these entities: P53-null HGSOC mutations preferentially enriched the PI3K/AKT/mTOR axis, whereas cervical cancer mutations converged on the MAPK/ERK pathway. Conclusion P53 negativity masks divergent oncogenic trajectories driven by fundamentally different mechanisms. In HGSOC, the P53-negative phenotype arises from intrinsic TP53 loss-of-function mutations, whereas in cervical cancer it predominantly reflects HPV E6-mediated post-translational degradation of wild-type P53 protein. Consequently, cervical carcinogenesis appears to rely on alternative pathway dysregulation (e.g., MAPK/ERK activation) independent of primary TP53 inactivation. These findings highlight the necessity of histology-specific, mechanism-driven therapeutic strategies that incorporate HPV status in P53-negative gynecological malignancies.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-18
DOI
https://doi.org/10.21203/rs.3.rs-11508050/v1
Primary Topic
Ovarian cancer diagnosis and treatment
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Divergent Mutational Landscapes and Clinical Outcomes in P53-Negative High-Grade Serous Ovarian Carcinoma Versus Cervical Cancer

Ruichao Chen, Tonghui Cai, Ping Qin, Zilong Song et al.
Research Square
Ovarian cancer diagnosis and treatment
preprint

Divergent Mutational Landscapes and Clinical Outcomes in P53-Negative High-Grade Serous Ovarian Carcinoma Versus Cervical Cancer

Ruichao Chen, Tonghui Cai, Ping Qin, Zilong Song, Qingping Jiang, Wei Zhang, Li Zhao, Tianyu Wang
preprint en

Abstract

Objective P53 negativity is a shared diagnostic feature of both some high-grade serous ovarian carcinoma (HGSOC) and cervical cancer, yet the underlying mechanisms remain poorly defined. This study aimed to elucidate the distinct pathogenic mechanisms and signaling dependencies that distinguish P53-negative HGSOC from P53-negative cervical cancer. Methods Hematoxylin and eosin (H&E) and P53 immunohistochemistry (IHC) were performed on archival HGSOC and cervical cancer cohorts. Clinical parameters were collected for P53-negative cases, followed by comprehensive molecular profiling using targeted next-generation sequencing (NGS). Differentially mutated genes were subjected to Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses. Results Patients with P53-negative HGSOC were significantly older (≥ 50 years: 81.25% vs. 50%, P < 0.05) and exhibited a five-fold higher mortality rate (25% vs. 5%) than the P53-negative cervical cancer cohort. Molecular profiling revealed that all 16 P53-negative HGSOC cases harbored deleterious TP53 mutations, whereas P53-negative cervical cancers showed wild-type TP53 but high mutation frequencies in PIK3CA (33.33%) and TERT (27.78%); notably, the P53-negative phenotype in cervical cancer was attributable to E6 oncoprotein-driven ubiquitin-mediated proteasomal degradation of wild-type P53 rather than to TP53 gene inactivation. Pathway analysis further distinguished these entities: P53-null HGSOC mutations preferentially enriched the PI3K/AKT/mTOR axis, whereas cervical cancer mutations converged on the MAPK/ERK pathway. Conclusion P53 negativity masks divergent oncogenic trajectories driven by fundamentally different mechanisms. In HGSOC, the P53-negative phenotype arises from intrinsic TP53 loss-of-function mutations, whereas in cervical cancer it predominantly reflects HPV E6-mediated post-translational degradation of wild-type P53 protein. Consequently, cervical carcinogenesis appears to rely on alternative pathway dysregulation (e.g., MAPK/ERK activation) independent of primary TP53 inactivation. These findings highlight the necessity of histology-specific, mechanism-driven therapeutic strategies that incorporate HPV status in P53-negative gynecological malignancies.

Research Square
Third Affiliated Hospital of Guangzhou Medical University (CN), Guangzhou Medical University (CN)
Good health and well-being
Ovarian cancer diagnosis and treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon